Cidara Therapeutics, Inc.
CDTX
주식 순위
#3184
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
주가
$221.38
마지막 동기화: 2026-01-08
시가총액
$5.61B
변동 (1일)
0.00%
변동 (1년)
118.07%
국가
US
거래 Cidara Therapeutics, Inc. (CDTX)
카테고리
Healthcare
Cidara Therapeutics, Inc. (CDTX)의 수익
Sep 2025 기준 수익 TTM: $-184.80M
Cidara Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-184.80M입니다. 2023년에 회사는 $-25.07M의 수익을 올렸으며 이는 2022년의 수익 $-33.31M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Cidara Therapeutics, Inc.의 수익 기록 (2012 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-184.80M | 8.52% |
| 2024 | $-170.29M | 579.40% |
| 2023 | $-25.07M | -24.76% |
| 2022 | $-33.31M | -21.56% |
| 2021 | $-42.47M | -41.11% |
| 2020 | $-72.11M | 75.49% |
| 2019 | $-41.09M | -30.37% |
| 2018 | $-59.02M | 5.90% |
| 2017 | $-55.73M | 15.70% |
| 2016 | $-48.17M | 49.61% |
| 2015 | $-32.19M | 170.67% |
| 2014 | $-11.89M | 784.97% |
| 2013 | $-1.34M | 69.70% |
| 2012 | $-792.00K | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -2,954.38% |
US
|
|
| $-3.09B | 1,570.45% |
US
|
|
| $-4.02B | 2,073.27% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,155.55% |
NL
|
